UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Rating of “Buy” by Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $38.20.

A number of research analysts have weighed in on URGN shares. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Monday, March 10th. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Finally, HC Wainwright cut their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th.

UroGen Pharma Stock Up 1.6 %

URGN stock opened at $11.07 on Friday. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 1 year low of $9.03 and a 1 year high of $20.70. The company has a fifty day simple moving average of $10.45 and a 200 day simple moving average of $11.65. The firm has a market cap of $259.64 million, a PE ratio of -3.51 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. Sell-side analysts anticipate that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Institutional Trading of UroGen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. GSA Capital Partners LLP bought a new stake in UroGen Pharma in the third quarter valued at about $249,000. Intech Investment Management LLC bought a new stake in UroGen Pharma in the third quarter valued at about $155,000. Charles Schwab Investment Management Inc. increased its stake in UroGen Pharma by 9.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 90,493 shares of the company’s stock valued at $1,149,000 after acquiring an additional 7,576 shares during the period. FMR LLC increased its stake in UroGen Pharma by 575.1% in the third quarter. FMR LLC now owns 23,090 shares of the company’s stock valued at $293,000 after acquiring an additional 19,670 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the period. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.